Multistate Outbreak
Extensively Drug-resistant Pseudomonas aeruginosa Associated with Artificial Tears

CDC is investigating a multistate outbreak of extensively drug-resistant, carbapenemase-producing P. aeruginosa infections associated with multiple and different infection types, including eye infections. The investigation currently suggests artificial tears may be a common source of infection for many patients. The brand of artificial tears most commonly reported was EzriCare Artificial Tears. The manufacturer, Global Pharma, has initiated a voluntary recall to the consumer level of all unexpired lots of EzriCare Artificial Tears and Delsam Pharma’s Artificial Tears.

Eye Drops being administered.

CDC recommends that clinicians and patients stop using EzriCare and Delsam Pharma’s Artificial Tears products pending additional guidance from CDC and FDA.

What healthcare providers and facilities need to know:

The infections caused by this strain of bacteria are resistant to most antibiotics. They are challenging to treat and have the potential to spread rapidly, especially in healthcare settings. Follow infection control recommendations and consult with a specialist knowledgeable in the treatment of antibiotic-resistant bacteria to determine best treatment. Read the Health Alert Network advisory.

What patients need to know:

Patients who have used this product within the last 14 days should monitor for symptoms of eye infection. Seek medical care immediately if symptoms occur. Learn more about what symptoms to look for.